Illumina spinout Grail plans a UK study of an investigational next-generation sequencing blood test for early detection of multiple cancers early next year, in collaboration with other organizations. The study will enroll approximately 50,000 adults ages 50 to 77 with a significant smoking history but without a cancer diagnosis.
Grail to launch UK study of cancer test in early 2019
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.